NEWS
Trestle Biotherapeutics Wins Prestigious KidneyX Prize
SAN DIEGO [June 12, 2023] – Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program. Trestle is one of eight Artificial Kidney Prize Phase 2 winners announced today.
Trestle Biotherapeutics Joins the Wellcome Leap HOPE Program
SAN DIEGO [May 25, 2023] – Trestle Biotherapeutics today announced that it has joined the Wellcome Leap HOPE program.
Nature Outlook Highlights Research in the Fight Against Chronic Kidney Disease
Trestle Co-Founder and CSO, Alice Chen, Ph.D., provides insight on the fields of kidney stem cell biology and regenerative medicine, and how Trestle is advancing bioengineered kidney tissues for patients with kidney failure.
Trestle named as one of CONNECT San Diego’s “Cool Companies” for 2022
SAN DIEGO [April 5, 2022] – Trestle Biotherapeutics announced today that is has been selected as a “Cool Company” by Connect San Diego, an organization that helps promote San Diego’s top startups for funding.
Trestle Biotherapeutics Announces Formation of Advisory Board
SAN DIEGO [February 23, 2022] – Trestle Biotherapeutics, a private, San Diego-based company developing bioengineered therapies for patients living with kidney failure has today announced the formation of its advisory board. The Trestle Advisory Board is a balanced mix of academic and industry leaders who are world renowned scientific experts in the fields of 3D biofabrication, stem cell and developmental biology, tissue engineering, immunology, and nephrology.
Trestle Biotherapeutics Announces License Agreement with Kumamoto University for Key Stem Cell Biology Technology for Regenerative Medicine
SAN DIEGO–(BUSINESS WIRE)–Trestle Biotherapeutics, a private company based in San Diego, today announced that it has entered into a license agreement with Kumamoto University. Under the agreement, Trestle will gain access to foundational methods for the generation of specialized kidney cell types from human pluripotent stem cells.
Trestle Biotherapeutics Licenses Innovations from Harvard University to Develop 3D Biofabricated Tissues to Treat Kidney Failure
SAN DIEGO–(BUSINESS WIRE)–Trestle Biotherapeutics, a private company based in San Diego, today announced that it has entered into a license agreement with Harvard University. Under the agreement, Trestle will commercialize a suite of stem cell- and 3D biofabrication-based regenerative medicine technologies developed at Harvard’s Wyss Institute for Biologically Inspired Engineering, Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), and Brigham and Women’s Hospital.
Trestle Featured in TechCrunch Coverage of Top YC Biotech Companies
Trestle Biotherapeutics highlighted by TechCrunch as one of top biotech companies at Y Combinator’s W21 Demo Day
Trestle Biotherapeutics Backed by Y Combinator
Trestle Biotherapeutics is now backed by Y Combinator (YC), an elite start up accelerator that has launched more than 3000 companies, including Stripe, Airbnb, DoorDash, Coinbase, Instacart, Dropbox, Ginkgo Bioworks, and 64x Bio. Trestle accepted YC’s invitation to join the Winter 2021 cohort, and will be working directly with YC Partners Jared Friedman, Surbhi Sarna, and Tim Brady.
Trestle Founding Team Co-Authors Report Describing Benefits of 3D Bioprinting on Human Kidney Organoid Development
Founding scientists of Trestle co-author report describing use of automated bioprinting to enable human kidney organoid generation with improved throughput, reproducibility, scale, and nephron development. This work represents an important step forward in the areas of kidney tissue engineering and regenerative medicine.
Trestle Founding Team Co-Authors Report Describing Proof of Concept For Use of 3D Bioprinted Human Kidney Organoids in High Content Drug Screening
Founding scientists of Trestle co-author report demonstrating proof-of-concept for automated production of human kidney organoids using a 3D bioprinter. This approach enables rapid generation of large numbers of kidney organoids for use in high content compound screening.